Search clinical trials for: radioactive iodine - refractory

Total 9845 results

Humanitas Mirasole SpA
KU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaborators

Active, not recruiting

Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS (TUDCA-ALS)

Amyotrophic Lateral Sclerosis (ALS)

United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
Translational Research Center for Medical Innovation...
Kurosawa Hospital

Completed

Implant Radiation Therapy Using Radioactive Iodine in Treating Patients With Localized Prostate Cancer (J-POPS)

Prostate Cancer

Japan
Grupo Español de Tratamiento de Tumores de Cabeza...

Active, not recruiting

Spanish Study for Molecular Characterization of Thyroid Carcinoma (MOLTHY)

Differentiated Thyroid Carcinoma | Medullary Thyroid Carcinoma

Spain
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy

Prostate Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Refractory Anemia With Excess Blasts | Refractory... and other conditions

United States
Bayer

Completed

A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

Netherlands
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer

Thyroid

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
Emory University
Eisai Inc.

Terminated

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
Universiti Kebangsaan Malaysia Medical Centre

Completed

LIthium as Bridging thErapy Prior to Radioactiveiodine in hyperThYroidism (LIBERTY)

Hyperthyroidism/Thyrotoxicosis

Malaysia
The University of Hong Kong

Completed

HIFU Ablation vs Fixed-dose RAI-131 Therapy in Moderate-sized Non-toxic MNG

Non Toxic Multinodular Goiter | High Intensity Focused Ultrasound | RAI

Hong Kong
Peking Union Medical College Hospital

Completed

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Thyroid Cancer

China
University of Texas Southwestern Medical Center

Terminated

Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas

Pituitary Macroadenoma

United States
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Thyroid Cancer

United States, Canada, Germany, Korea, Republic of, Spain, France, Australia, Belgium, Denmark, Israel, Italy, Poland, Romania, Russian Federation, Sweden, United Kingdom
Universitair Ziekenhuis Brussel

Active, not recruiting

An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI for Hyperthyroidism.

Nodule Solitary Thyroid | Toxic Multinodular Goiter | Radioactive Iodine-Induced Hypothyroidism

Belgium
Tawam Hospital

Completed

Thyroid Cancer in United Arab Emirates

Cancer | Thyroid
Assiut University

Unknown

Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer

Radiation Exposure | Ovarian Insufficiency
Eisai Inc.

Completed

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Thyroid Cancer

United States, Australia, France, Poland, United Kingdom, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
Hutchison Medipharma Limited

Completed

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Thyroid Carcinoma

China
Nanjing First Hospital, Nanjing Medical University

Unknown

Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers (APT-01)

Metastasis | Thyroid | Apatinib

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
Mayo Clinic

Completed

Early Levothyroxine Post Radioactive Iodine

Graves' Disease

United States
AstraZeneca

Terminated

Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer (ASTRA)

Differentiated Thyroid Cancer

United States, Denmark, Italy, Sweden, Poland, Brazil, France, Germany
Peking University Third Hospital

Completed

CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer

Early Stage Non-small Cell Lung Cancer
Peking University Third Hospital

Completed

The Physical Dosimetry Study and Preliminary Clinical Results of 3D-printing Non Co-planar Template Assisted With CT-guidance for Iodine-125 Seed Brachytherapy in Pelvic Recurrent Rectum Carcinoma After Surgery and External Beam Radiotherapy

Rectum Cancer, Recurrent | Brachytherapy, Radioisotope
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Schering-Plough

Terminated

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Cancer

United States
Medstar Health Research Institute

Terminated

Comparison of I-124 and I-131 Radiopharmacokinetics in DTC Patients With Thyroid Hormone Withdrawal

Thyroid Cancer

United States
Medstar Health Research Institute

Terminated

Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)

Thyroid Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

Pain | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Terminated

Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive Iodine

Thyroid Abnormalities

United States
University of Helsinki
Helsinki University Central Hospital

Unknown

The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy

Thyroid Neoplasms

Finland
Xiayun He, MD

Unknown

Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

Thyroid Cancer

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
Susan Knox
GlaxoSmithKline; Corixa Corporation

Completed

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Recurrent Thyroid Gland Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Follicular Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

Recurrent Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary Carcinoma

United States, Canada
National Cancer Center, Korea

Unknown

Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer

Thyroid Neoplasms

Korea, Republic of
GlaxoSmithKline

Completed

A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies (RIT-II-001)

Lymphoma, Non-Hodgkin
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR); Ontario Ministry of Health and...

Completed

Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer

Thyroid Cancer

Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Quality of Life | Lymphoma

United States
Zhongda Hospital

Unknown

A Trail of a Novel Tracheal Radioactive Stent for the Malignant Airway Obstruction

Malignant Airway Obstruction

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Mayo Clinic

Completed

Shared Decision Making in Graves Disease - Graves Disease (GD) Choice

Hyperthyroidism | Thyroid Disease | Graves' Disease

United States

Search clinical trials for: radioactive iodine - refractory

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations